Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00311092 | Oral cavity | NEOLP | microtubule polymerization or depolymerization | 26/2005 | 122/18723 | 4.52e-04 | 4.06e-03 | 26 |
GO:004351811 | Oral cavity | NEOLP | negative regulation of DNA damage response, signal transduction by p53 class mediator | 7/2005 | 15/18723 | 4.72e-04 | 4.21e-03 | 7 |
GO:005149417 | Oral cavity | NEOLP | negative regulation of cytoskeleton organization | 32/2005 | 163/18723 | 5.07e-04 | 4.48e-03 | 32 |
GO:004351614 | Oral cavity | NEOLP | regulation of DNA damage response, signal transduction by p53 class mediator | 11/2005 | 34/18723 | 5.70e-04 | 4.96e-03 | 11 |
GO:005068631 | Oral cavity | NEOLP | negative regulation of mRNA processing | 10/2005 | 29/18723 | 5.71e-04 | 4.96e-03 | 10 |
GO:00181082 | Oral cavity | NEOLP | peptidyl-tyrosine phosphorylation | 61/2005 | 375/18723 | 5.88e-04 | 5.08e-03 | 61 |
GO:001063932 | Oral cavity | NEOLP | negative regulation of organelle organization | 57/2005 | 348/18723 | 7.37e-04 | 6.03e-03 | 57 |
GO:000647631 | Oral cavity | NEOLP | protein deacetylation | 21/2005 | 101/18723 | 2.11e-03 | 1.39e-02 | 21 |
GO:00429822 | Oral cavity | NEOLP | amyloid precursor protein metabolic process | 20/2005 | 95/18723 | 2.28e-03 | 1.47e-02 | 20 |
GO:004298721 | Oral cavity | NEOLP | amyloid precursor protein catabolic process | 15/2005 | 68/18723 | 4.87e-03 | 2.65e-02 | 15 |
GO:004277031 | Oral cavity | NEOLP | signal transduction in response to DNA damage | 30/2005 | 172/18723 | 4.92e-03 | 2.67e-02 | 30 |
GO:003111021 | Oral cavity | NEOLP | regulation of microtubule polymerization or depolymerization | 18/2005 | 88/18723 | 5.08e-03 | 2.75e-02 | 18 |
GO:003560131 | Oral cavity | NEOLP | protein deacylation | 21/2005 | 112/18723 | 7.48e-03 | 3.74e-02 | 21 |
GO:190331116 | Prostate | BPH | regulation of mRNA metabolic process | 111/3107 | 288/18723 | 2.28e-19 | 1.17e-16 | 111 |
GO:000838018 | Prostate | BPH | RNA splicing | 147/3107 | 434/18723 | 5.17e-19 | 2.29e-16 | 147 |
GO:004348418 | Prostate | BPH | regulation of RNA splicing | 71/3107 | 148/18723 | 6.14e-19 | 2.53e-16 | 71 |
GO:190290318 | Prostate | BPH | regulation of supramolecular fiber organization | 133/3107 | 383/18723 | 2.40e-18 | 8.73e-16 | 133 |
GO:005068415 | Prostate | BPH | regulation of mRNA processing | 64/3107 | 137/18723 | 1.73e-16 | 3.82e-14 | 64 |
GO:000037517 | Prostate | BPH | RNA splicing, via transesterification reactions | 114/3107 | 324/18723 | 2.19e-16 | 4.53e-14 | 114 |
GO:000037717 | Prostate | BPH | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYRK1A | SNV | Missense_Mutation | | c.217G>C | p.Asp73His | p.D73H | Q13627 | protein_coding | deleterious(0) | benign(0.364) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DYRK1A | SNV | Missense_Mutation | | c.1744C>G | p.His582Asp | p.H582D | Q13627 | protein_coding | tolerated_low_confidence(0.18) | possibly_damaging(0.84) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DYRK1A | SNV | Missense_Mutation | | c.1976N>T | p.Ser659Phe | p.S659F | Q13627 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.962) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK1A | SNV | Missense_Mutation | | c.1626C>A | p.Phe542Leu | p.F542L | Q13627 | protein_coding | tolerated(0.05) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DYRK1A | SNV | Missense_Mutation | | c.161N>T | p.Ser54Phe | p.S54F | Q13627 | protein_coding | deleterious_low_confidence(0.01) | benign(0.044) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
DYRK1A | SNV | Missense_Mutation | | c.46C>T | p.Arg16Trp | p.R16W | Q13627 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.454) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
DYRK1A | SNV | Missense_Mutation | | c.492G>C | p.Leu164Phe | p.L164F | Q13627 | protein_coding | deleterious(0.02) | probably_damaging(0.949) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
DYRK1A | SNV | Missense_Mutation | | c.2230N>C | p.Asp744His | p.D744H | Q13627 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
DYRK1A | SNV | Missense_Mutation | | c.183G>C | p.Gln61His | p.Q61H | Q13627 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.626) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DYRK1A | SNV | Missense_Mutation | | c.1898A>G | p.Tyr633Cys | p.Y633C | Q13627 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.984) | TCGA-E2-A15E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme1WO2011135259 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme15-1 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme23MPPDerivatives | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 249565842 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme13INDY | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 405560505 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme4Upper | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme12-3 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme18 | | |